Physical and Chemical Stability of Palonosetron Hydrochloride with Fluorouracil and with Gemcitabine Hydrochloride during Simulated Y-site Administration
Author(s): Trissel Lawrence A, Zhang Yanping
Issue: Jul/Aug 2005 - Human Hormone Replacement Therapy
View All Articles in Issue
Page(s): 320-322
Download in electronic PDF format for $75
Abstract: The objective of this study was to evaluate the physical and chemical stability of undiluted palonosetron 50 µg/mL as the hydrochloride with fluorouracil 16 mg/mL, and with gemcitabine 10 mg/mL as the hydrochloride, in 5% dextrose injection during simulated Y-site administration. Triplicate test samples were prepared by admixing 7.5 mL of palonosetron hydrochloride with 7.5 mL of the fluorouracil and gemcitabine hydrochloride admixtures. Physical stability was assessed by using a multistep evaluation procedure that included both turbidimetric and particulate measurements as well as visual inspection. Chemical stability was assessed by using stability-indicating high-performance liquid chromatographic analytical techniques that determined drug concentrations. Evaluations were performed initially upon mixing and 1 and 4 hours after mixing. The samples were clear and colorless when viewed in normal fluorescent room light and when viewed with a Tyndall beam. Measured turbidity remained unchanged; particulate cont
Related Keywords:
stability, palonosetron hydrochloride, gemcitabine hydrochloride, chemotherapy agents, fluorouracil
Related Categories:
CANCER AND AIDS, GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES
Printer-Friendly Version
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Physical and Chemical Stability of Palonosetron Hydrochloride with Fluorouracil and with Gemcitabine Hydrochloride during Simulated Y-site Administration
Trissel Lawrence A, Zhang Yanping
|
Jul/Aug 2005
Pg. 320-322
|
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 156-160
|
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 170-173
|
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration
Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
|
Jul/Aug 2008
Pg. 368-371
|
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration
Trissel Lawrence A, Xu Quanyun A
|
May/Jun 2005
Pg. 238-241
|
Compatibility and Stability of Palonosetron Hydrochloride and Propofol During Simulated Y-Site Administration
Trissel Lawrence A, Trusley Craig, Kupiec Thomas C, Ben Michel
|
Jan/Feb 2009
Pg. 78-80
|
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
|
Nov/Dec 2007
Pg. 520-524
|
Physical and Chemical Stability of Palonosetron Hydrochloride with Lorazepam and Midazolam Hydrochloride during Simulated Y-Site Administration
Trissel Lawrence A, Xu Quanyun A
|
May/Jun 2005
Pg. 235-237
|
Physical and Chemical Stability of Palonosetron with Metoclopramide and Promethazine During Simulated Y-Site Administration
Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
|
Jan/Feb 2007
Pg. 82-85
|
Physical and Chemical Stability of Palonosetron Hydrochloride with Dacarbazine and with Methylprednisolone Sodium Succinate During Simulated Y-Site Administration
Trissel Lawrence A, Xu Quanyun A, Zhang Yanping
|
May/Jun 2006
Pg. 234-236
|
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration
Ben Michel, Kupiec Thomas C, Trusley Craig, Trissel Lawrence A
|
Sep/Oct 2008
Pg. 460-462
|
Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic Syringes
Xu Quanyun A, Trissel Lawrence A, Pham Lien
|
Jan/Feb 2002
Pg. 66-69
|
Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Bupivacaine Hydrochloride Packaged in Plastic Syringes
Trissel Lawrence A, Xu Quanyun A, Pham Lien
|
Jan/Feb 2002
Pg. 70-73
|
Compatibility and Stability of Ranitidine Hydrochloride with Six Cephalosporins During Simulated Y-Site Administration
Inagaki Kazuhiro, Kambara Motoya, Mizuno Munemichi, Gill Mark A, Nishida Mikio
|
Jul/Aug 1998
Pg. 318-321
|
Compatibility of Amiodarone Hydrochloride with Vasopressin During Simulated Y-site Administration
Ramaley Corrine C, Li Feng, Du Chengan
|
Sep/Oct 2013
Pg. 436-438
|
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
Wu George, Yeung Stanley, Chen Frank
|
Jan/Feb 2017
Pg. 76-82
|
Physical and Chemical Stability of Hydromorphone Hydrochloride 1.5- and 80-mg/mL Packaged in Plastic Syringes
Trissel Lawrence A, Xu Quanyun A, Pham Lien
|
Jan/Feb 2002
Pg. 74-76
|
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
|
Nov/Dec 2018
Pg. 516-526
|
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration
Zhang Yang, Scarlett Cameron, Hutson Paul
|
Jan/Feb 2012
Pg. 82-85
|
Compatibility Screening of Bivalirudin During Simulated Y-Site Administration with Other Drugs
Trissel Lawrence A, Saenz Christopher
|
Jul/Aug 2002
Pg. 311-315
|
| Return to Top |
